U.S. markets close in 15 minutes

Alnylam Pharmaceuticals Inc (DUL.BE)

Berlin - Berlin Delayed Price. Currency in EUR
177.84+4.36 (+2.51%)
As of 08:08PM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close173.48
Bid179.50 x N/A
Ask181.04 x N/A
Day's Range174.78 - 179.34
52 Week Range113.36 - 230.45
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateApr 26, 2023 - May 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • American City Business Journals

      Alnylam CEO Yvonne Greenstreet sees growing the company as 'a wonderful challenge'

      When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.

    • Zacks

      Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

      Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    • InvestorPlace

      3 Growth Stocks That Could Disrupt the Healthcare Industry

      Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health